Mednax, Inc. (MD): Price and Financial Metrics


Mednax, Inc. (MD): $26.90

0.72 (+2.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MD POWR Grades


  • MD scores best on the Value dimension, with a Value rank ahead of 75.75% of US stocks.
  • MD's strongest trending metric is Value; it's been moving down over the last 198 days.
  • MD ranks lowest in Sentiment; there it ranks in the 3rd percentile.

MD Stock Summary

  • Mednax Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 78.44% of US listed stocks.
  • The ratio of debt to operating expenses for Mednax Inc is higher than it is for about 81.9% of US stocks.
  • As for revenue growth, note that MD's revenue has grown -50.65% over the past 12 months; that beats the revenue growth of just 6.22% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Mednax Inc, a group of peers worth examining would be MAXR, CEQP, KMPH, ESBA, and BRT.
  • Visit MD's SEC page to see the company's official filings. To visit the company's web site, go to www.mednax.com.

MD Price Target

For more insight on analysts targets of MD, see our MD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.50 Average Broker Recommendation 2 (Hold)

MD Stock Price Chart Interactive Chart >

Price chart for MD

MD Price/Volume Stats

Current price $26.90 52-week high $29.25
Prev. close $26.18 52-week low $11.62
Day low $26.25 Volume 553,900
Day high $27.07 Avg. volume 936,738
50-day MA $26.25 Dividend yield N/A
200-day MA $21.74 Market Cap 2.32B

Mednax, Inc. (MD) Company Bio


MEDNAX Inc. provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company was founded in 1979 and is based in Sunrise, Florida.

MD Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$26.90$3.32 -88%

We started the process of determining a valid price forecast for Mednax Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Mednax Inc ranked in the 15th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for MD, they are:

  • Its compound free cash flow growth rate, as measured over the past 5.56 years, is -0.14% -- higher than merely 11.44% of stocks in our DCF forecasting set.
  • Mednax Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -6.06. This coverage rate is greater than that of only 11% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • As a business, Mednax Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-88%
1%-88%
2%-88%
3%-88%
4%-87%
5%-87%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MD, try TECH, ZBH, IIN, LCI, and LMNX.


MD Latest News Stream


Event/Time News Detail
Loading, please wait...

MD Latest Social Stream


Loading social stream, please wait...

View Full MD Social Stream

Latest MD News From Around the Web

Below are the latest news stories about Mednax Inc that investors may wish to consider to help them evaluate MD as an investment opportunity.

Mednax 2021 First Quarter Conference Call/Webcast Scheduled for Friday, May 7, 2021

Mednax 2021 First Quarter Conference Call/Webcast Scheduled for Friday, May 7, 2021

Yahoo | April 22, 2021

Oteemo Helps Mednax Reduce Deployment Time from Months to Minutes

Oteemo, Inc., a leader in DevSecOps transformation and cloud native application development, today announced its successful transformation effort with Mednax, Inc. (NYSE: MD), the national medical group specializing in prenatal, neonatal and pediatric services. Oteemo helped Mednax establish its DevSecOps practice and accelerate deployment time from months to minutes.

Yahoo | April 21, 2021

Here's Why You Should Retain Mednax (MD) in Your Portfolio

Riding high on strategic initiatives and telehealth medicine, MEDNAX (MD) holds potential to reap benefits for investors.

Yahoo | March 23, 2021

Mednax (MD) Up 31.6% Since Last Earnings Report: Can It Continue?

Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 20, 2021

Mednax (MD) Ties Up With NightLight to Offer Better Pediatric Care

Mednax (MD) collaborates with NighLight with an aim to offer enhanced pediatric care in Texas.

Yahoo | March 17, 2021

Read More 'MD' Stories Here

MD Price Returns

1-mo 4.71%
3-mo 4.06%
6-mo 63.03%
1-year 94.36%
3-year -41.05%
5-year -61.20%
YTD 9.62%
2020 -11.69%
2019 -15.79%
2018 -38.25%
2017 -19.83%
2016 -6.98%

Continue Researching MD

Here are a few links from around the web to help you further your research on Mednax Inc's stock as an investment opportunity:

Mednax Inc (MD) Stock Price | Nasdaq
Mednax Inc (MD) Stock Quote, History and News - Yahoo Finance
Mednax Inc (MD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8194 seconds.